-
Amendments have been made to the elution time regulations for products containing coagulation factor IX (FIX),ensuring optimal product purity and efficacy.
-
The incremental dosing schedule in clinical trials has been refined. initially, doses of 1 × 1013 vg kg−1, 1.5 × 1012 vg kg−1 were used, but this has been modified to 5 × 1012 vg kg−1, followed by 7.5 × 1012 vg kg−1 to optimize therapeutic response and minimize potential adverse effects.
-
Several laboratory endpoints-total bilirubin (TBIL), alkaline phosphatase, and glutamyltranspeptidase-have been removed as primary endpoints in Phase 1/2 trials. This decision streamlines the evaluation process, focusing on the moast clinically relevant indicators of treatment success.
-
A pivotal Phase 3 study now incorporates flexibility in assessing FIX-Padua activity levels. You can utilize either the Theissenmekon platform with the actin-FSL aPTT reagent or the Werfen platform with the HemosIL SynthASil reagent, providing options for reliable and consistent measurement.
-
Enrollment criteria have been updated to broaden patient access. I’ve found that optimizing these criteria is crucial for representative trial populations. Specifically, the description of previous hepatitis B infections (acute and chronic) and other chronic diseases has been clarified, and the restriction regarding hepatitis C antibodies has been removed.
reporting summary
Further facts on research design is available in the Nature Portfolio reporting Summary linked to this article.